Physician profile
Ben Yan
NPI 1417153701
$6,875.14
in general payments reported to CMS, 2019-2025
47 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,515 · 2020: $578 · 2022: $1,314 · 2023: $1,549 · 2024: $716 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,448 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,447.78 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $775.42 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $656.01 | 2019-2025 | Enhertu, Imfinzi |
| Lilly USA, LLC | $605.81 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $483.62 | 2019-2024 | |
| Genentech USA, INC. | $478.36 | 2019-2023 | Venclexta, Lunsumio, Phesgo |
| Merck Sharp & Dohme LLC | $381.49 | 2019-2024 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $329.66 | 2019-2024 | Opdivo |
| Daiichi Sankyo INC. | $313.60 | 2019-2024 | Enhertu, Injectafer |
| Genzyme Corporation | $285.23 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $282.19 | 2019-2024 | |
| Incyte Corporation | $247.70 | 2019-2025 | Jakafi |
| Janssen Biotech, INC. | $247.25 | 2019-2023 | |
| Seagen INC. | $163.95 | 2019-2023 | Tukysa |
| Gilead Sciences, INC. | $127.20 | 2023-2024 | Trodelvy |
| Eisai INC. | $112.23 | 2019-2024 |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Yan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.